Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer

Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.

The top 3

1. Impact on Clinical Outcomes: Recent trial data presented at a European cancer conference demonstrates that the mRNA vaccine, when administered in tandem with an immunotherapy drug, is effective in decreasing the incidence of cancer recurrence and patient mortality.

Sources

• NPR Health

Open the full topic